Tiotropium therapy and mortality risk in COPD patients: The most severe, the most protected?

Italo Sampablo, Mauro Carone, Sabina Antonela Antoniu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Importance of the field: Tiotropium bromidum is an inhaled long acting anticholinergic used as first line monotherapy in stable COPD due to its beneficial effects on the lung function, respiratory symptoms, quality of life or disease morbidity. However there is limited data on its effects on mortality. Areas covered in this review: The results of the UPLIFT (Understanding Potential Long-Term Impacts on Function with Tiotropium) study evaluating the effects of 4 year therapy with tiotropium on above mentioned outcomes including mortality. What the reader will gain: Tiotropium demonstrated an uniform beneficial effect on mortality risk reduction but subset analyses yielded relevant results as well. Take home message: On long-term basis tiotropium therapy can reduce mortality rate overall and can exert such protective effects in various subsets such as patients with very severe COPD.

Original languageEnglish
Pages (from-to)1439-1441
Number of pages3
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number8
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Chronic Obstructive Pulmonary Disease
Mortality
Therapeutics
Cholinergic Antagonists
Risk Reduction Behavior
Quality of Life
Tiotropium Bromide
Morbidity
Lung

Keywords

  • COPD
  • Mortality
  • Tiotropium
  • UPLIFT

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Tiotropium therapy and mortality risk in COPD patients : The most severe, the most protected? / Sampablo, Italo; Carone, Mauro; Antoniu, Sabina Antonela.

In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 8, 06.2010, p. 1439-1441.

Research output: Contribution to journalArticle

@article{b1a686c51de94b19ab27f3db40cfa26e,
title = "Tiotropium therapy and mortality risk in COPD patients: The most severe, the most protected?",
abstract = "Importance of the field: Tiotropium bromidum is an inhaled long acting anticholinergic used as first line monotherapy in stable COPD due to its beneficial effects on the lung function, respiratory symptoms, quality of life or disease morbidity. However there is limited data on its effects on mortality. Areas covered in this review: The results of the UPLIFT (Understanding Potential Long-Term Impacts on Function with Tiotropium) study evaluating the effects of 4 year therapy with tiotropium on above mentioned outcomes including mortality. What the reader will gain: Tiotropium demonstrated an uniform beneficial effect on mortality risk reduction but subset analyses yielded relevant results as well. Take home message: On long-term basis tiotropium therapy can reduce mortality rate overall and can exert such protective effects in various subsets such as patients with very severe COPD.",
keywords = "COPD, Mortality, Tiotropium, UPLIFT",
author = "Italo Sampablo and Mauro Carone and Antoniu, {Sabina Antonela}",
year = "2010",
month = "6",
doi = "10.1517/14656561003745916",
language = "English",
volume = "11",
pages = "1439--1441",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Tiotropium therapy and mortality risk in COPD patients

T2 - The most severe, the most protected?

AU - Sampablo, Italo

AU - Carone, Mauro

AU - Antoniu, Sabina Antonela

PY - 2010/6

Y1 - 2010/6

N2 - Importance of the field: Tiotropium bromidum is an inhaled long acting anticholinergic used as first line monotherapy in stable COPD due to its beneficial effects on the lung function, respiratory symptoms, quality of life or disease morbidity. However there is limited data on its effects on mortality. Areas covered in this review: The results of the UPLIFT (Understanding Potential Long-Term Impacts on Function with Tiotropium) study evaluating the effects of 4 year therapy with tiotropium on above mentioned outcomes including mortality. What the reader will gain: Tiotropium demonstrated an uniform beneficial effect on mortality risk reduction but subset analyses yielded relevant results as well. Take home message: On long-term basis tiotropium therapy can reduce mortality rate overall and can exert such protective effects in various subsets such as patients with very severe COPD.

AB - Importance of the field: Tiotropium bromidum is an inhaled long acting anticholinergic used as first line monotherapy in stable COPD due to its beneficial effects on the lung function, respiratory symptoms, quality of life or disease morbidity. However there is limited data on its effects on mortality. Areas covered in this review: The results of the UPLIFT (Understanding Potential Long-Term Impacts on Function with Tiotropium) study evaluating the effects of 4 year therapy with tiotropium on above mentioned outcomes including mortality. What the reader will gain: Tiotropium demonstrated an uniform beneficial effect on mortality risk reduction but subset analyses yielded relevant results as well. Take home message: On long-term basis tiotropium therapy can reduce mortality rate overall and can exert such protective effects in various subsets such as patients with very severe COPD.

KW - COPD

KW - Mortality

KW - Tiotropium

KW - UPLIFT

UR - http://www.scopus.com/inward/record.url?scp=77952120470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952120470&partnerID=8YFLogxK

U2 - 10.1517/14656561003745916

DO - 10.1517/14656561003745916

M3 - Article

C2 - 20446856

AN - SCOPUS:77952120470

VL - 11

SP - 1439

EP - 1441

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 8

ER -